Literature DB >> 25015940

Clinical importance of different calreticulin gene mutation types in wild-type JAK2 essential thrombocythemia and myelofibrosis patients.

Chun Qiao1, Chao Sun1, Yuan Ouyang1, Ju-Juan Wang1, Si-Xuan Qian1, Jian-Yong Li2, Su-Jiang Zhang2.   

Abstract

Entities:  

Keywords:  Janus kinase 2 mutation; MPL; calreticulin

Mesh：

Substances：

Year:  2014        PMID： 25015940      PMCID： PMC4181265          DOI： 10.3324/haematol.2014.109199

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  11 in total

Review 1.  Myeloproliferative disorders.

Authors:  Ross L Levine; D Gary Gilliland
Journal:  Blood       Date:  2008-09-15       Impact factor: 22.113

2.  Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis).

Authors:  Tiziano Barbui; Guido Finazzi; Alessandra Carobbio; Juergen Thiele; Francesco Passamonti; Elisa Rumi; Marco Ruggeri; Francesco Rodeghiero; Maria Luigia Randi; Irene Bertozzi; Heinz Gisslinger; Veronika Buxhofer-Ausch; Valerio De Stefano; Silvia Betti; Alessandro Rambaldi; Alessandro M Vannucchi; Ayalew Tefferi
Journal:  Blood       Date:  2012-10-01       Impact factor: 22.113

Review 3.  Genetics of myeloproliferative neoplasms.

Authors:  Aaron D Viny; Ross L Levine
Journal:  Cancer J       Date:  2014 Jan-Feb       Impact factor: 3.360

4.  Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.

Authors:  Ross L Levine; Martha Wadleigh; Jan Cools; Benjamin L Ebert; Gerlinde Wernig; Brian J P Huntly; Titus J Boggon; Iwona Wlodarska; Jennifer J Clark; Sandra Moore; Jennifer Adelsperger; Sumin Koo; Jeffrey C Lee; Stacey Gabriel; Thomas Mercher; Alan D'Andrea; Stefan Fröhling; Konstanze Döhner; Peter Marynen; Peter Vandenberghe; Ruben A Mesa; Ayalew Tefferi; James D Griffin; Michael J Eck; William R Sellers; Matthew Meyerson; Todd R Golub; Stephanie J Lee; D Gary Gilliland
Journal:  Cancer Cell       Date:  2005-04       Impact factor: 31.743

Review 5.  The Ph-positive and Ph-negative myeloproliferative neoplasms: some topical pre-clinical and clinical issues.

Authors:  Richard A Van Etten; Steffen Koschmieder; Francois Delhommeau; Danilo Perrotti; Tessa Holyoake; Animesh Pardanani; Ruben Mesa; Tony Green; Amr R Ibrahim; Tariq Mughal; Robert Peter Gale; John Goldman
Journal:  Haematologica       Date:  2011-01-17       Impact factor: 9.941

6.  Somatic mutations of calreticulin in myeloproliferative neoplasms.

Authors:  Thorsten Klampfl; Heinz Gisslinger; Ashot S Harutyunyan; Harini Nivarthi; Elisa Rumi; Jelena D Milosevic; Nicole C C Them; Tiina Berg; Bettina Gisslinger; Daniela Pietra; Doris Chen; Gregory I Vladimer; Klaudia Bagienski; Chiara Milanesi; Ilaria Carola Casetti; Emanuela Sant'Antonio; Virginia Ferretti; Chiara Elena; Fiorella Schischlik; Ciara Cleary; Melanie Six; Martin Schalling; Andreas Schönegger; Christoph Bock; Luca Malcovati; Cristiana Pascutto; Giulio Superti-Furga; Mario Cazzola; Robert Kralovics
Journal:  N Engl J Med       Date:  2013-12-10       Impact factor: 91.245

7.  Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms.

Authors:  Pontus Lundberg; Axel Karow; Ronny Nienhold; Renate Looser; Hui Hao-Shen; Ina Nissen; Sabine Girsberger; Thomas Lehmann; Jakob Passweg; Martin Stern; Christian Beisel; Robert Kralovics; Radek C Skoda
Journal:  Blood       Date:  2014-01-29       Impact factor: 22.113

8.  Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia.

Authors:  Giada Rotunno; Carmela Mannarelli; Paola Guglielmelli; Annalisa Pacilli; Alessandro Pancrazzi; Lisa Pieri; Tiziana Fanelli; Alberto Bosi; Alessandro M Vannucchi
Journal:  Blood       Date:  2013-12-26       Impact factor: 22.113

9.  JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes.

Authors:  Elisa Rumi; Daniela Pietra; Virginia Ferretti; Thorsten Klampfl; Ashot S Harutyunyan; Jelena D Milosevic; Nicole C C Them; Tiina Berg; Chiara Elena; Ilaria C Casetti; Chiara Milanesi; Emanuela Sant'antonio; Marta Bellini; Elena Fugazza; Maria C Renna; Emanuela Boveri; Cesare Astori; Cristiana Pascutto; Robert Kralovics; Mario Cazzola
Journal:  Blood       Date:  2013-12-23       Impact factor: 22.113

10.  CALR exon 9 mutations are somatically acquired events in familial cases of essential thrombocythemia or primary myelofibrosis.

Authors:  Elisa Rumi; Ashot S Harutyunyan; Daniela Pietra; Jelena D Milosevic; Ilaria C Casetti; Marta Bellini; Nicole C C Them; Chiara Cavalloni; Virginia V Ferretti; Chiara Milanesi; Tiina Berg; Emanuela Sant'Antonio; Emanuela Boveri; Cristiana Pascutto; Cesare Astori; Robert Kralovics; Mario Cazzola
Journal:  Blood       Date:  2014-02-19       Impact factor: 22.113
View more
  8 in total

1.  Mutations and long-term outcome of 217 young patients with essential thrombocythemia or early primary myelofibrosis.

Authors:  F Palandri; R Latagliata; N Polverelli; A Tieghi; M Crugnola; B Martino; M Perricone; M Breccia; E Ottaviani; N Testoni; F Merli; F Aversa; G Alimena; M Cavo; G Martinelli; L Catani; M Baccarani; N Vianelli
Journal:  Leukemia       Date:  2015-03-24       Impact factor: 11.528

2.  A meta-analysis comparing clinical characteristics and outcomes in CALR-mutated and JAK2V617F essential thrombocythaemia.

Authors:  Yining Yang; Xiaorui Wang; Chun Wang; Youwen Qin
Journal:  Int J Hematol       Date:  2014-12-25       Impact factor: 2.490

3.  Frequencies, Laboratory Features, and Granulocyte Activation in Chinese Patients with CALR-Mutated Myeloproliferative Neoplasms.

Authors:  Haixiu Guo; Xiuhua Chen; Ruiyuan Tian; Jianmei Chang; Jianlan Li; Yanhong Tan; Zhifang Xu; Fanggang Ren; Junxia Zhao; Jie Pan; Na Zhang; Xiaojuan Wang; Jianxia He; Wanfang Yang; Hongwei Wang
Journal:  PLoS One       Date:  2015-09-16       Impact factor: 3.240

4.  Validation of the differential prognostic impact of type 1/type 1-like versus type 2/type 2-like CALR mutations in myelofibrosis.

Authors:  P Guglielmelli; G Rotunno; T Fanelli; A Pacilli; G Brogi; L Calabresi; A Pancrazzi; A M Vannucchi
Journal:  Blood Cancer J       Date:  2015-10-16       Impact factor: 11.037

5.  The Mutation Profile of Calreticulin in Patients with Myeloproliferative Neoplasms and Acute Leukemia.

Authors:  Jingyi Wang; Jianguo Hao; Na He; Chunyan Ji; Daoxin Ma
Journal:  Turk J Haematol       Date:  2015-08-06       Impact factor: 1.831

6.  [Clinical significance of JAK2、CALR and MPL gene mutations in 1 648 Philadelphia chromosome negative myeloproliferative neoplasms patients from a single center].

Authors:  M Y Li; H Y Chao; A N Sun; H Y Qiu; Z M Jin; X W Tang; Y Han; C C Fu; S N Chen; D P Wu
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2017-04-14

7.  Mutation profile in Indian primary myelofibrosis patients and its clinical implications.

Authors:  Vinod R Patil; S Chandrakala; Shruti Mantri; Rajesh Patil; Nilesh Wasekar; Farah Jijina
Journal:  South Asian J Cancer       Date:  2019 Jul-Sep

8.  Screening PCR Versus Sanger Sequencing: Detection of CALR Mutations in Patients With Thrombocytosis.

Authors:  Ji Hun Jeong; Hwan Tae Lee; Ja Young Seo; Yiel Hea Seo; Kyung Hee Kim; Moon Jin Kim; Jae Hoon Lee; Jinny Park; Jun Shik Hong; Pil Whan Park; Jeong Yeal Ahn
Journal:  Ann Lab Med       Date:  2016-07       Impact factor: 3.464
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.